There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

Metastatic breast cancer treatment with the combination of PCS6422 and capecitabine (NGC-Cap) may increase the cancer-killing ...

The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining ...

In this video, Eleonora Teplinsky, MD, discusses results of the HER2CLIMB-05 study, showing that adding tucatinib to first-line maintenance therapy improved patient outcomes in HER2-positive ...

HER2CLIMB-05 successfully met its primary endpoint of progression-free survival (PFS), with the addition of tucatinib ...

"All rapidly growing cells in the body are affected by chemotherapy. The cancer cells are targeted, but hair cells and the ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...